A Phase 1 interventional study of U-500R in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Terminated at 1 site in United States. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2023-10-23.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing insulin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 1 of them phase 3. Insulin · Diabetes Mellitus, Type 2.
Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, this one is the 48th largest by enrollment, is one of 6 that started in 2016, is one of 5 in phase 1, and was the 37th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing insulin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 55–80
Ohio State University · Sites in United States
Ages 18+ · Women only
Emory University · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 8 · Phase 4 20
First in 1995; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 60 across the 54 interventional studies. Of the 44 that completed or were terminated, 19 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 227th largest by enrollment of the 232 interventional ones that give a count, is one of 7 that started in 2016, is one of 76 in phase 1, and was the 114th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing insulin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06251635Centre for Addiction and Mental HealthEffects of Antipsychotics on Brain Insulin Action in Females | 2026-12-31 |
| NCT06699810Emory UniversityModeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity | 2027-01 |
| NCT07293715Ohio State UniversityPermissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this two-part study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. In Part A, each participant will receive two treatments, a single dose and a single dose with continuous infusion of U-500R insulin, both administered just under the skin. Participants who complete Part A will continue into Part B where they will be assigned to 1 of 2 treatments with U-500R insulin, injected either twice or three times daily under the skin for 5-10 days. This study can last from 7-14 weeks including initial screening and follow up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bolus of U-500R administered via single subcutaneous (SC) injection.
Drug: U-500R
Bolus of U-500R administered via continuous subcutaneous insulin infusion (CSII).
Drug: U-500R
U-500R administered thrice-daily (TID) via SC injection under steady state conditions for 5 to 10 days
Drug: U-500R
U-500R administered twice-daily (BID) via SC injection under steady state conditions for 5 to 10 days
Drug: U-500R
Also known as: Humulin R U-500, LY041001, Humulin
Part A: Pharmacokinetics (PK): Time to Maximum Drug Concentration (Tmax) of U-500R
Part A: Pharmacokinetics (PK): Time to Maximum Drug Concentration (Tmax) of U-500R.
Time frame: Period 1 and 2: -0.5, 0, 0.5, 1, 2, 3, 4, 6, 7, 8, 12, 16, 24 hours (h) post dose
Part B: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to 24 Hours Postdose (AUC[0-24]) of U-500R
Part B: Pharmacokinetics: Area Under the Concentration Versus Time Curve from Zero to 24 Hours Postdose (AUC\[0-24\]) of U-500R.
Time frame: Period 3: -0.5, 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose
Part B: Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of U-500R
Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of U-500R.
Time frame: Period 3: -0.5, 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose
Part B: Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax) of U-500R
Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax) of U-500R.
Time frame: Period 3 day 1: 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18h post dose
Part A: Pharmacokinetics: Area Under The Concentration Versus Time Curve From Time Zero to Last Time Point With A Measurable Concentration (AUC[0-tlast]) of U-500R
Part A: Pharmacokinetics: Area Under The Concentration Versus Time Curve From Time Zero to Last Time Point With A Measurable Concentration (AUC\[0-tlast\]) of U-500R.
Time frame: Period 1 and 2: -0.5, 0, 0.5, 1, 2, 3, 4, 6, 7, 8, 12, 16, 24h post dose
Part A: Pharmacodynamics (PD): Time to Rmax (tRmax) of U-500R
Part A: Pharmacodynamics (PD): Time to Rmax (tRmax) of U-500R.
Time frame: Period 1 and 2: 0, 0.5, 1, 2, 3, 4, 6, 7, 8, 12, 16, 24h post dose
Part B: Pharmacokinetics: Time to Maximum Concentration (Tmax) of U-500R
Part B: Pharmacokinetics: Time to Maximum Concentration (Tmax) of U-500R.
Time frame: Period 3: -0.5, 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose
Part B: Pharmacodynamics: Total Amount of Glucose Infused (Gtot) of U-500R
Pharmacodynamics: Total Amount of Glucose Infused (Gtot) of U-500R.
Time frame: Period 3: 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose
Part B: Pharmacodynamics: Time to Rmax (tRmax) of U-500R
Part B: Pharmacodynamics: Time to Rmax (tRmax) of U-500R.
Time frame: Period 3: 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose
Two parts study with Part A (Periods 1 \& 2) \& Part B (Period 3). Part A:Participants received study drug either by subcutaneous(SC) or continuous subcutaneous insulin infusion (CSII) as per the dosing sequence. Part B: Participants received study drug via SC injection either twice daily (BID) or three times daily (TID) as per the dosing sequence.
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 3 | 2 | 3 | 3 |
| Received at least one dose of study drug | 3 | 2 | 3 | 3 |
| Completed | 3 | 2 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 3 | 2 | 3 | 3 |
| Completed | 3 | 2 | 2 | 3 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 3 | 2 | 2 | 3 |
| Completed | 3 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
Part A: Pharmacokinetics (PK): Time to Maximum Drug Concentration (Tmax) of U-500R.
| Hours (h) | 100-U Bolus U-500R SC | 100-U Bolus U-500R CSII |
|---|---|---|
| Part A: Pharmacokinetics (PK): Time to Maximum Drug Concentration (Tmax) of U-500R | 6 (0.5 to 8) | 5 (0.5 to 12) |
Part B: Pharmacokinetics: Area Under the Concentration Versus Time Curve from Zero to 24 Hours Postdose (AUC\[0-24\]) of U-500R.
| Picomoles hour per liter (pmol*h/L) | U-500R BID | U-500R TID |
|---|---|---|
| Part B: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to 24 Hours Postdose (AUC[0-24]) of U-500R | 7790 ± 57 | 11700 ± 77 |
Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of U-500R.
| Pico mole per liter (Pmol/L) | U-500R BID | U-500R TID |
|---|---|---|
| Part B: Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of U-500R | 699 ± 47 | 1050 ± 82 |
Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax) of U-500R.
| Milligram per Minute (mg/min) | U-500R BID | U-500R TID |
|---|---|---|
| Part B: Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax) of U-500R | 524 ± 30 | 588 ± 28 |
Part A: Pharmacokinetics: Area Under The Concentration Versus Time Curve From Time Zero to Last Time Point With A Measurable Concentration (AUC\[0-tlast\]) of U-500R.
| Picomole hours per liter (pmol^h/L) | 100-U Bolus U-500R SC | 100-U Bolus U-500R CSII |
|---|---|---|
| Part A: Pharmacokinetics: Area Under The Concentration Versus Time Curve From Time Zero to Last Time Point With A Measurable Concentration (AUC[0-tlast]) of U-500R | 5230 ± 35 | 6070 ± 70 |
Part A: Pharmacodynamics (PD): Time to Rmax (tRmax) of U-500R.
| Hour (h) | 100-U Bolus U-500R SC | 100-U Bolus U-500R CSII |
|---|---|---|
| Part A: Pharmacodynamics (PD): Time to Rmax (tRmax) of U-500R | 8.50 ± 31 | 8.53 ± 35 |
Part B: Pharmacokinetics: Time to Maximum Concentration (Tmax) of U-500R.
| Hours | U-500R BID | U-500R TID |
|---|---|---|
| Part B: Pharmacokinetics: Time to Maximum Concentration (Tmax) of U-500R | 15 (5 to 18) | 15 (7 to 15) |
Pharmacodynamics: Total Amount of Glucose Infused (Gtot) of U-500R.
| Grams (g) | U-500R BID | U-500R TID |
|---|---|---|
| Part B: Pharmacodynamics: Total Amount of Glucose Infused (Gtot) of U-500R | 441 ± 27 | 510 ± 28 |
Part B: Pharmacodynamics: Time to Rmax (tRmax) of U-500R.
| Hours | U-500R BID | U-500R TID |
|---|---|---|
| Part B: Pharmacodynamics: Time to Rmax (tRmax) of U-500R | 12.4 ± 64 | 13.8 ± 7 |
Collected over Up to 72 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 100-U Bolus U-500R SC | 0/11 (0%) | 0/11 (0%) | 4/11 (36.4%) |
| 100-U Bolus U-500R CSII | 0/11 (0%) | 0/11 (0%) | 3/11 (27.3%) |
| U-500R BID | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| U-500R TID | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | 100-U Bolus U-500R SC | 100-U Bolus U-500R CSII | U-500R BID | U-500R TID |
|---|---|---|---|---|
| Oedema peripheralGeneral disorders | 0/11 | 0/11 | 1/4 | 0/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/11 | 0/11 | 1/4 | 0/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/11 | 0/11 | 1/4 | 0/6 |
| Infusion site extravasationGeneral disorders | 0/11 | 0/11 | 0/4 | 1/6 |
| Upper respiratory tract infectionInfections and infestations | 0/11 | 0/11 | 0/4 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 1/11 | 0/11 | 0/4 | 0/6 |
| Gastrointestinal disorderGastrointestinal disorders | 0/11 | 1/11 | 0/4 | 0/6 |
| Medical device site swellingGeneral disorders | 0/11 | 1/11 | 0/4 | 0/6 |
| Peripheral swellingGeneral disorders | 1/11 | 0/11 | 0/4 | 0/6 |
| Procedural complicationInjury, poisoning and procedural complications | 1/11 | 0/11 | 0/4 | 0/6 |
All randomized participants.
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 56.2 ± 7.3 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 3 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | Overall |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 7 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 6 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Body mass index(Kilogram per square meter (kg/m^2)) | Overall |
|---|---|
| Mean | 39.63 ± 8.59 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2016 to primary completion in May 2017, 16 months.
Results were first posted in Oct 2023, 6 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin